3,564 reports of this reaction
3.9% of all GEMCITABINE HYDROCHLORIDE reports
#3 most reported adverse reaction
THROMBOCYTOPENIA is the #3 most commonly reported adverse reaction for GEMCITABINE HYDROCHLORIDE, manufactured by Armas Pharmaceuticals Inc.. There are 3,564 FDA adverse event reports linking GEMCITABINE HYDROCHLORIDE to THROMBOCYTOPENIA. This represents approximately 3.9% of all 92,220 adverse event reports for this drug.
Patients taking GEMCITABINE HYDROCHLORIDE who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is moderately reported among GEMCITABINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to thrombocytopenia, the following adverse reactions have been reported for GEMCITABINE HYDROCHLORIDE:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 3,564 FDA reports for GEMCITABINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 3.9% of all adverse event reports for GEMCITABINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience thrombocytopenia while taking GEMCITABINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.